ReviewCells2021
Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Efficacy and safety of immune checkpoint inhibitors for brain metastases of non-small cell lung cancer: a systematic review and network meta-analysis.Frontiers in oncology · 2025Pooled it
- Neurosurgical Resection for De Novo Brain Metastases from Non-Small Cell Lung Cancer: Real-World Evidence for Multidisciplinary Decision-Making.Journal of clinical medicine · 2026Article
- Intrathecal chemotherapy for leptomeningeal metastasis of non-small-cell lung cancer: a systematic review.Frontiers in pharmacology · 2026Review
- Analysis of prognostic factors influencing brain metastasis in EGFR-mutant lung adenocarcinoma and comparison of prognostic assessment models.Oncology letters · 2026Article
- Optimizing primary tumor resection decisions for non-small cell lung cancer patients with brain metastases: analysis based on the SEER database and development and external validation of predictive models.Journal of thoracic disease · 2025Article
- Immunotherapy promoting spontaneous regression of non-irradiated brain Metastases following gamma knife treatment: an intracranial abscopal effect?Neurosurgical review · 2025Article
- Immuno-inflammatory signature for predicting therapeutic response and survival after stereotactic radiosurgery in NSCLC patients with brain metastases: a retrospective cohort study.Frontiers in immunology · 2025Article
- Article
- Analysis of high‑risk factors for brain metastasis and prognosis after prophylactic cranial irradiation in limited‑stage small cell lung cancer.Oncology letters · 2024Article
- Clinicopathological characteristics and prognosis of synchronous brain metastases from non-small cell lung cancer compared with metachronous brain metastases.Frontiers in oncology · 2024Article
- Machine learning-based prognostic models and factors influencing the benefit of surgery on primary lesion for patients with lung cancer brain metastases.American journal of cancer research · 2024Article
- Clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinoma.Frontiers in oncology · 2024Article
- Article
- Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advancedTranslational lung cancer research · 2023Article
- First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).Cancer immunology, immunotherapy : CII · 2023Article
- Survival and prognostic factors in patients undergoing the resection of solitary brain metastasis from non-small cell lung cancer: a retrospective cohort study.Journal of thoracic disease · 2022Article
- CircKIF4A promotes non-small cell lung cancer proliferation and metastasis through MiR-1238/CLDN14 axis.Aging · 2022Article
- Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors and has high morbidity and mortality rates. Central nervous system (CNS) metastasis is one of the most frequent complications in patients with NSCLC and seriously affects the quality of life (QOL) and overall survival (OS) of patients, with a median OS of untreated patients of only 1-3 months. There are various treatment methods for NSCLC CNS metastasis, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, which do not meet the requirements of patients in terms of improving OS and QOL. There are still many problems in the treatment of NSCLC CNS metastasis that need to be solved urgently. This review summarizes the research progress in the treatment of NSCLC CNS metastasis to provide a reference for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.